These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28750917)

  • 21. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.
    Tangkijvanich P; Chittmittraprap S; Poovorawan K; Limothai U; Khlaiphuengsin A; Chuaypen N; Wisedopas N; Poovorawan Y
    J Viral Hepat; 2016 Jun; 23(6):427-38. PubMed ID: 26387494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy.
    Erken R; Zaaijer HL; Willemse SB; Bakker E; Takkenberg BB; Reesink HW; Kootstra NA
    Ann Hepatol; 2021 Dec; 26():100540. PubMed ID: 34583061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
    Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
    J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
    Liao H; Liu Y; Li X; Wang J; Chen X; Zou J; Li Q; Liu L; Wang J; Huang B; Lu F; Xu D
    Antivir Ther; 2019; 24(2):105-115. PubMed ID: 30511941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
    Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
    Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B.
    van Campenhout MJH; Rijckborst V; Brouwer WP; van Oord GW; Ferenci P; Tabak F; Akdogan M; Pinarbasi B; Simon K; de Knegt RJ; Boonstra A; Janssen HLA; Hansen BE
    J Viral Hepat; 2019 Oct; 26(10):1156-1163. PubMed ID: 31135084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive role of early treatment dynamics of HBV RNA and HBcrAg for HBeAg seroconversion in children with chronic hepatitis B.
    Lai X; OuYang W; Li S; Qiu J; Zhang H; Jiang T; Qin X; Tang L; Gu Y; Yao Z; Peng S
    J Med Virol; 2024 May; 96(5):e29670. PubMed ID: 38773810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis.
    Zhang ZQ; Wang YB; Lu W; Liu DP; Shi BS; Zhang XN; Huang D; Li XF; Zhou XL; Ding RR
    Ann Lab Med; 2019 Jan; 39(1):67-75. PubMed ID: 30215232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B.
    Zhang ZQ; Zhang XN; Lu W; Wang YB; Weng QC; Feng YL
    BMC Gastroenterol; 2017 Dec; 17(1):140. PubMed ID: 29202690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
    Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
    Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients.
    Zhao J; Bian D; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
    Front Cell Infect Microbiol; 2023; 13():1083912. PubMed ID: 37065191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
    Vecchi A; Rossi M; Tiezzi C; Fisicaro P; Doselli S; Gabor EA; Penna A; Montali I; Ceccatelli Berti C; Reverberi V; Montali A; Fletcher SP; Degasperi E; Sambarino D; Laccabue D; Facchetti F; Schivazappa S; Loggi E; Coco B; Cavallone D; Rosselli Del Turco E; Massari M; Pedrazzi G; Missale G; Verucchi G; Andreone P; Brunetto MR; Lampertico P; Ferrari C; Boni C
    Gut; 2024 Sep; 73(10):1737-1748. PubMed ID: 39033025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B.
    Wang J; Zhang Z; Zhu L; Zhang Q; Zhang S; Pan Y; Liu J; Cao F; Fan T; Xiong Y; Yin S; Yan X; Chen Y; Zhu C; Li J; Liu X; Wu C; Huang R
    Virulence; 2024 Dec; 15(1):2404965. PubMed ID: 39317345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
    Testoni B; Scholtès C; Plissonnier ML; Paturel A; Berby F; Facchetti F; Villeret F; Degasperi E; Scott B; Hamilton A; Heil M; Lampertico P; Levrero M; Zoulim F
    Gut; 2024 Mar; 73(4):659-667. PubMed ID: 37879886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.